Giant cell arteritis (GCA), historically called temporal arteritis, is an immune-mediated vasculitis involving medium- and large-sized arteries. It occurs almost exclusively in adults over age 50 and can produce headache, scalp tenderness, jaw pain, constitutional symptoms, and visual disturbances.
The most feared complication is permanent vision loss caused by ischemia to structures supplying the optic nerve and retina.
For this reason, suspected GCA represents a time-sensitive clinical condition.
Clinical Pearl: When GCA is strongly suspected, corticosteroid treatment should not be delayed while waiting for confirmatory testing—particularly when visual symptoms are present.
GCA causes granulomatous inflammation within the walls of affected arteries.
The inflammatory process produces:
Arterial inflammation → vessel-wall swelling and remodeling → luminal narrowing → reduced blood flow → tissue ischemia
Although historically called temporal arteritis, the disease is not limited to the temporal arteries. It may involve branches of the:
Therefore, giant cell arteritis is a more accurate term than temporal arteritis.
Age is one of the strongest diagnostic clues. GCA occurs in adults 50 years and older, with incidence increasing substantially with advancing age. The average age at diagnosis is approximately 70 years.
Additional epidemiological characteristics include:
Clinical Pearl: A new or unusual headache in an adult over age 50 should prompt consideration of secondary headache disorders, including GCA.
GCA can present in several different ways. Common manifestations include:
Some patients develop dramatic cranial symptoms, while others initially present only with fatigue, fever, weight loss, or generalized muscle discomfort.
Headache is one of the most common presenting symptoms. The headache is typically:
Although the disease is traditionally associated with temporal headache, pain may occur in other locations. Patients may describe pain involving the:
This is clinically important because GCA should not be excluded simply because the headache is not located over the temporal artery.
Inflammation of superficial cranial arteries can produce significant scalp sensitivity. Patients may report discomfort when:
Scalp tenderness in an older adult with a new headache substantially increases concern for GCA when accompanied by other compatible findings.
The temporal arteries should be carefully inspected and palpated. Possible abnormalities include:
However, a normal temporal artery examination does not exclude GCA. Because the inflammatory process may affect arterial segments unevenly, normal and abnormal portions of the vessel can occur adjacent to one another. This phenomenon is often described as skip lesions.
Jaw claudication is one of the most important clinical clues to GCA. Patients typically experience pain or fatigue in the jaw muscles during repetitive chewing.
For example: Patient begins eating → jaw discomfort develops with continued chewing → symptoms improve after resting the jaw.
This occurs because blood flow cannot adequately meet the increased metabolic demands of the chewing muscles. Jaw claudication should be distinguished from:
In GCA, the exertional relationship with chewing is particularly characteristic.
Visual symptoms are among the most concerning manifestations of GCA. Patients may experience:
Transient episodes may precede irreversible blindness. Therefore: Transient visual loss in suspected GCA is a warning sign—not reassurance because vision returned.
Inflammation can compromise arteries supplying the optic nerve. One major mechanism of permanent visual loss is arteritic anterior ischemic optic neuropathy (AAION). Reduced blood flow causes ischemic injury to the optic nerve. Once significant ischemic visual loss occurs, recovery may be limited or impossible. Treatment therefore focuses heavily on preventing visual loss in the initially unaffected eye.
Not every patient initially presents with dramatic cranial symptoms. Systemic inflammation may produce:
In some older adults, constitutional symptoms may dominate the initial presentation. Unexplained fever or inflammatory marker elevation in an older adult may therefore occasionally lead to evaluation for GCA.
GCA and polymyalgia rheumatica (PMR) are closely related inflammatory disorders. A substantial proportion of patients with GCA have associated PMR symptoms. PMR typically produces:
Symptoms are generally most pronounced after periods of inactivity. Importantly, PMR produces pain and stiffness rather than true primary muscle weakness.
Recognizing the GCA–PMR Connection:
A patient with established PMR who develops new headache, scalp tenderness, jaw claudication, or visual symptoms requires urgent assessment for GCA. Similarly, patients presenting with suspected GCA should be questioned about shoulder stiffness, hip-girdle pain, morning stiffness, difficulty raising the arms, or difficulty getting out of bed or a chair because of pain and stiffness.
No single clinical symptom independently confirms or excludes GCA. Evaluation typically combines:
Clinical presentation + Inflammatory markers + Vascular imaging and/or Temporal artery biopsy
The diagnostic process should occur rapidly, but treatment should not be unnecessarily delayed in patients with strong clinical suspicion.
Two important laboratory tests are:
Other laboratory findings may include thrombocytosis, normocytic anemia, and elevated alkaline phosphatase. ESR and CRP are useful but nonspecific—they may also be elevated with infection, malignancy, or other autoimmune diseases. Conversely, normal inflammatory markers make GCA less likely but do not absolutely exclude it in every clinical circumstance.
Temporal artery biopsy has historically been a major confirmatory test for GCA. A segment of the temporal artery is surgically removed and examined histologically. Pathology may demonstrate:
Giant cells themselves are not required in every biopsy specimen for the pathology to support GCA.
Skip Lesions and False-Negative Biopsy:
One challenge with temporal artery biopsy is that inflammation may occur in discontinuous segments (Inflamed artery → normal segment → inflamed artery). Because of these skip lesions, a biopsy can occasionally miss the affected portion of the artery. Obtaining an adequate specimen length and integrating pathology with the clinical presentation are therefore important. A negative biopsy does not automatically exclude GCA when clinical suspicion remains high.
Vascular ultrasound has become increasingly important in the evaluation of suspected GCA. A characteristic finding is the halo sign, representing inflammatory thickening of the arterial wall.
Ultrasound offers several advantages:
In experienced centers, ultrasound may serve as a first-line diagnostic imaging technique. Its accuracy, however, depends substantially on equipment and operator expertise.
Because GCA can involve large vessels beyond the temporal arteries, additional imaging may be appropriate. Options include CT angiography, MR angiography, PET imaging, and vascular ultrasound to identify inflammation involving the aorta, subclavian arteries, axillary arteries, and other major arterial branches.
Routine head CT or standard brain MRI alone generally does not diagnose GCA because the primary pathology involves blood vessels rather than brain tissue itself.
The primary objective of treatment is to suppress arterial inflammation rapidly and prevent irreversible ischemic complications. When clinical suspicion is sufficiently high, begin glucocorticoid therapy promptly. Treatment should not be delayed solely to wait for temporal artery biopsy, ultrasound, specialist consultation, or additional laboratory results.
Systemic glucocorticoids remain a cornerstone of initial GCA treatment. For patients without visual ischemia, treatment commonly begins with high-dose oral glucocorticoids, followed by gradual dose reduction after disease control is achieved. Treatment often continues for many months and sometimes considerably longer, depending on disease severity, visual involvement, relapse history, inflammatory markers, comorbidities, and glucocorticoid toxicity.
Visual symptoms dramatically increase urgency. Patients with threatened or established visual ischemia may require very high-dose glucocorticoid therapy, often using an initial intravenous regimen, depending on the clinical situation and specialist guidance. The goal is to reduce the risk of further visual deterioration, involvement of the opposite eye, and additional ischemic complications.
Clinical Pearl: New visual symptoms plus suspected GCA require emergency evaluation. Treatment should not wait for biopsy confirmation.
Tocilizumab is a monoclonal antibody targeting the interleukin-6 (IL-6) receptor, which plays an important role in the inflammatory process underlying GCA. Tocilizumab may reduce disease relapse, help maintain remission, reduce cumulative glucocorticoid exposure, and facilitate glucocorticoid tapering. It is particularly important in patients with relapsing disease or those at high risk from prolonged corticosteroid exposure.
Additional immunosuppressive medications may be considered in selected patients. Methotrexate may have a role as a glucocorticoid-sparing agent, particularly when tocilizumab is inappropriate. Treatment decisions should be individualized and frequently involve rheumatology.
Long-term glucocorticoid therapy can produce significant adverse effects, including osteoporosis, hyperglycemia, hypertension, weight gain, infection, cataracts, glaucoma, skin thinning, and adrenal suppression. Patients require ongoing assessment for treatment-related toxicity.
Because GCA often affects older adults who may already have increased fracture risk, glucocorticoid-induced osteoporosis is particularly important. Management may include calcium optimization, vitamin D optimization, weight-bearing exercise when appropriate, bone mineral density assessment, and bisphosphonate therapy in patients meeting risk-based criteria.
Older approaches sometimes recommended routine low-dose aspirin for most patients with GCA. Contemporary management is more selective. Aspirin may be considered when a patient has another cardiovascular indication or certain high-risk vascular features, but routine aspirin for every patient is not universally recommended because the potential ischemic benefit must be weighed against bleeding risk.
GCA is not exclusively a cranial disease. Inflammation may involve the aorta and its major branches, increasing the risk of aortic aneurysm, aortic dissection, arterial stenosis, limb claudication, and blood-pressure differences between arms. Long-term clinical surveillance is therefore important even after cranial symptoms have resolved.
Several disorders may resemble GCA, including migraine, tension-type headache, cluster headache, cervicogenic headache, temporomandibular joint disease, dental disease, trigeminal neuralgia, infection, malignancy, other systemic vasculitides, and nonarteritic ischemic optic neuropathy.
The combination of older age + new headache + jaw claudication + inflammatory marker elevation ± visual symptoms should raise substantial concern for GCA.
Age ≥50 with a new or substantially changed headache, especially when accompanied by:
Visual symptoms make the situation especially urgent because treatment delay can result in irreversible blindness.
New headache + age over 50 + jaw claudication or visual symptoms = think giant cell arteritis.
GCA is one of the most important secondary headache disorders to recognize because an apparently straightforward new headache may precede irreversible visual loss or other major vascular complications. Diagnosis relies on clinical suspicion supported by inflammatory markers, vascular imaging, and/or temporal artery biopsy. However, the central management principle is simple:
When GCA is strongly suspected, protect vision first—confirm the diagnosis without delaying treatment.
Educational content only. Suspected GCA—particularly with transient or persistent visual symptoms—requires urgent medical assessment. Diagnostic testing and treatment should follow current rheumatology, ophthalmology, and vascular guidelines and be individualized to the patient.
